

**Compliant Claim Listing Pursuant to 37 C.F.R. § 1.121**

1-30 (Canceled)

31. (Previously presented) A method for determining whether a subject has an astrocytoma, the method comprising assaying for CD81 expression a diagnostic sample of cells of astrocytic lineage of the subject, wherein no detection of expression of CD81 in cells of astrocytic lineage of the subject is diagnostic of an astrocytoma.

32. (Previously presented) The method of claim 31, wherein the diagnostic sample of cells of astrocytic lineage of the subject is assayed *in vitro*.

33. (Currently amended) A method for assessing the efficacy of astrocytoma therapy in a subject who has undergone or is undergoing treatment for an astrocytoma, the method comprising assaying for CD81 expression a diagnostic sample of cells of astrocytic tumor cells of the subject, wherein no detection of expression of CD81 in astrocytic tumor cells of the subject is indicative of unsuccessful astrocytoma therapy.

34. (Currently amended) The method of claim 33, wherein the diagnostic sample of cells of astrocytic tumor cells lineage of the subject is assayed *in vitro*.



35. (Previously presented) The method of claim 31, wherein the subject is a mammal.

36. (Previously presented) The method of claim 31, wherein the subject is a human.

37. (Previously presented) The method of claim 31, wherein CD81 expression is assayed using an immunological technique.

38. (Previously presented) The method of claim 37, wherein the immunological technique utilizes an antibody, an Fab fragment, or an F(ab'), fragment.

39. (Previously presented) The method of claim 38, wherein the antibody, Fab fragment, or F(ab'), fragment is monoclonal.

40. (Previously presented) The method of claim 38, wherein the antibody, Fab fragment, or F(ab'), fragment is polyclonal.

41. (Previously presented) The method of claim 38, wherein the antibody, Fab fragment, or F(ab'); fragment is labeled with a detectable marker.

42. (Previously presented) The method of claim 41, wherein the detectable marker is a nonradioactive or a fluorescent marker.



43. (Previously presented) The method of claim 41, wherein the detectable marker is a radioactive marker.
44. (Previously presented) The method of claim 31, wherein CD81 expression is assayed using hybridization analysis.
45. (Previously presented) The method of claim 44, wherein the hybridization analysis is a northern blot analysis for CD81 mRNA in mRNA extracted from cells of astrocytic lineage.
46. (Previously presented) The method of claim 44, wherein the hybridization analysis utilizes an RNA probe.
47. (Previously presented) The method of claim 44, wherein the hybridization analysis utilizes a DNA probe.
48. (Previously presented) The method of claim 32, wherein CD81 expression is assayed using RT-PCR.
49. (Previously presented) The method of claim 31, wherein CD81 expression is assayed using fluorescence imaging techniques.
- 50 (Previously presented) The method of claim 31, wherein CD81 expression is assayed using radiation detection.



51. (Previously presented) The method of claim 32, wherein CD81 expression is assayed using immunocytofluoresmetry.

52. (Previously presented) The method of claim 33, wherein the subject is a human.

53. (Previously presented) The method of claim 33, wherein CD81 expression is assayed using an immunological technique.

54. (Previously presented) The method of claim 53, wherein the immunological technique utilizes an antibody, an Fab fragment, or an F(ab')<sub>2</sub> fragment.

55. (Previously presented) The method of claim 54, wherein the antibody, Fab fragment, or F(ab'), fragment is monoclonal.

56. (Previously presented) The method of claim 54, wherein the antibody, Fab fragment, or F(ab'), fragment is labeled with a detectable marker.

57. (Previously presented) The method of claim 33, wherein CD81 expression is assayed using hybridization analysis.

58. (Previously presented) The method of claim 57, wherein the hybridization analysis is a northern blot analysis for CD81 mRNA in mRNA extracted from cells of astrocytic lineage.



59. (Previously presented) The method of claim 57, wherein the hybridization analysis utilizes an RNA probe.

60. (Previously presented) The method of claim 57, wherein the hybridization analysis utilizes a DNA probe.

61. (Previously presented) The method of claim 34, wherein CD81 expression is assayed using RT-PCR.

62. (Previously presented) The method of claim 33, wherein CD81 expression is assayed using fluorescence imaging techniques.

63. (Previously presented) The method of claim 33, wherein CD81 expression is assayed using radiation detection.

64. (Previously presented) The method of claim 34, wherein CD81 expression is assayed using immunocytofluorometry.

